The Manufacturers Life Insurance Company Purchases New Position in DaVita Inc. $DVA

The Manufacturers Life Insurance Company acquired a new stake in DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 29,392 shares of the company’s stock, valued at approximately $6,539,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Root Financial Partners LLC boosted its position in shares of DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after buying an additional 105 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in DaVita during the 2nd quarter valued at about $43,000. Caitlin John LLC bought a new stake in shares of DaVita in the fourth quarter worth approximately $34,000. Compass Financial Management LLC purchased a new position in shares of DaVita during the second quarter valued at approximately $72,000. Finally, Sankala Group LLC bought a new position in DaVita during the fourth quarter valued at approximately $39,000. Institutional investors own 90.12% of the company’s stock.

Insider Activity at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Truist Financial cut their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and increased their target price for the company from $201.00 to $220.00 in a report on Friday, August 7th. Finally, Oppenheimer set a $220.00 price target on DaVita in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, DaVita has a consensus rating of “Hold” and a consensus price target of $221.75.

DaVita Stock Up 0.0%

NYSE DVA opened at $180.72 on Monday. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $247.49. The company has a market capitalization of $11.53 billion, a P/E ratio of 14.79, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88. The stock’s 50-day moving average price is $211.96 and its 200-day moving average price is $183.37.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. During the same period in the previous year, the company posted $2.95 EPS. The firm’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.